RxDoctor Payments Data

Michael Dao, MD

Family Medicine · Grand Prairie, TXNPI 1205838588

Payments from drug & device makers

$17,653in general payments, 2019–2025

Across 962 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • plus $8K from 44 others

What the payments were for

  • Consulting fees$1,2007%
  • Travel & lodging$820%
  • Food & beverage$16,34293%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,653 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$59,961
Medicare patients
112
Services billed
3,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$75,580
OzempicSemaglutide35$61,162
KerendiaFinerenone13$23,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$23,170
EliquisApixaban22$20,579
JanuviaSitagliptin Phosphate12$20,536
VascepaIcosapent Ethyl13$13,833
LinzessLinaclotide13$12,580
Tresiba Flextouch U-200Insulin Degludec16$10,471
Omega-3 Acid Ethyl Esters21$4,650
Febuxostat20$2,618
Nano 2nd Gen Pen NeedlePen Needle, Diabetic25$2,568
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide92$2,493
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid60$2,452
Atorvastatin Calcium303$2,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,243$75,58082 claims
Novo NordiskOzempic$1,810$61,16235 claims
BayerKerendia$202$23,31113 claims
GSKTrelegy Ellipta$1,640$23,17013 claims
PfizerEliquis$504$20,57922 claims
MerckJanuvia$566$20,53612 claims
AbbVieLinzess$2,318$12,58013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grand Prairie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →